GLP-1 Treatments Pose Significant Risk to Greggs, Analysts Warn

Jefferies analysts have identified GLP-1 treatments as a significant threat to the business operations of Greggs. Bloomberg posted on X that these treatments, which are used for weight management, could impact the bakery chain's sales. The analysts suggest that as more people turn to GLP-1 medications for weight loss, there may be a decline in demand for Greggs' products, which are often high in calories. This potential shift in consumer behavior could pose challenges for the company, which is known for its pastries and baked goods. The report highlights the need for Greggs to adapt its offerings to align with changing consumer preferences. The analysts emphasize the importance of monitoring this trend closely as it could have long-term implications for the company's market position.